Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neuroblastoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Solid Tumor 1Relapsed Solid Tumors 1Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1

Interventions

Paclitaxel 12Gemcitabine 9atezolizumab 8Carboplatin 8Bevacizumab 6tocilizumab 4navitoclax 4liposomal doxorubicin 4Irinotecan 4Erlotinib Hydrochloride 4Cetuximab 4Sunitinib 3Oxaliplatin 3Leucovorin 3Injections 3Fluorouracil 3Docetaxel 3Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2tislelizumab 2temsirolimus 2ridaforolimus 2plocabulin 2pembrolizumab 2pazopanib 2olaparib 2obinutuzumab 2linifanib 2fludarabine 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumors × Cefixime × Clear all
NCT00186979 2017-04-26

Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors

St. Jude Children's Research Hospital

Phase 1 Completed
34 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡